Business
Ionis to hold fourth quarter and full year 2025 financial results webcast
CARLSBAD, Calif., February 11, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results and highlight progress on key programs.
About this update from Ionis Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/8bb93f737e347f510d1218a7486313bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ww4QCkDs3EgD.OhyAEAjqQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8bb93f737e347f510d1218a7486313bd","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/mFdIII3KNiN6UU10vzwPGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/8bb93f737e347f510d1218a7486313bd","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Webcast scheduled for Wednesday, February 25 at 11:30 a.m. Eastern Time","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"CARLSBAD, Calif., February 11, 2026--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2025 financial results and highlight progress on key programs.","length":305,"tagName":"p"},{"type":"text","content":"The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.","length":160,"tagName":"p"},{"type":"text","content":"About Ionis Pharmaceuticals, Inc.","length":33,"tagName":"p"},{"type":"text","content":"For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.","length":667,"tagName":"p"},{"type":"text","content":"View source version on businesswire.com: https://www.businesswire.com/news/home/20260211190610/en/"...